Elan, Wyeth Take an Inside-Out Approach to Alzheimer's Vaccine
The long-running saga of Elan's (ELN) attempt to come up with a vaccine for Alzheimer's disease continues. There have been bold attempts, setbacks, rethinks, more setbacks, and now they're starting up again. Dosing of the latest version of their vaccine against the beta-amyloid protein, known as ACC-001, was suddenly halted in April when one patient came down with a skin lesion which was thought to be possibly autoimmune-linked vasculitis.
Biopsy results didn't confirm that, though, and the Elan/Wyeth (WYE) partnership is resuming clinical studies. I'm not sure what that couple of months has done to their trial design; I assume that they've just started enrolling new patients and will continue with them, while continuing to monitor the former dosage groups. Maybe, though, there's a way to continue with some of those people and not lose all the time, effort, and data.
The idea of an amyloid vaccine has always excited and alarmed me in equal measure. But that's how I feel about the immune system in general, come to think of it. We have enough cellular firepower to completely destroy ourselves from the inside out - keeping that on a leash to where it (mostly) only goes after what it's supposed to is extremely impressive.
Now, I think that the usual sorts of vaccines are one of the great public health advances of civilization, but they work so well because they're targeted to outside agents (viral coat proteins and the like). Even so, there's a disturbingly large part of the population that remain suspicious of all vaccinations - I say "disturbing" not least because if that population gets too large, the efficacy of vaccination in general could be crippled. But what will these people think about a vaccine that's targeted to an endogenous protein? My immunology may need brushing up, but I can't think of any other example of such.
One thing that may keep this from becoming a huge issue, though, is that an amyloid vaccine, if it succeeds, will be targeted at the elderly rather than at children. And it'll be something that will have an effect against a disease that everyone can see right in front of them, rather than preventing diseases that most people have only read about in books. We'll be back at the situation that prevailed when the polio vaccine was introduced: no one had much doubt that the vaccine was better than the disease.
But even a vaccine fan like me still has room to admire, from a distance, the nerve of this approach. The brain is a special case, immunologically, and letting slip the dogs of war in there is not an intrinsically safe idea. But Alzheimer's is an intrinsically nasty disease...
Get Seeking Alpha Free Stock Alerts by Email!
Get Free Stock Alerts by Email!
ETFs In Focus
-
Editor's Picks
-
Most Popular
- Opportunity in Emerging Markets Amidst This Panic
- iPhone Sales Drastically Surpass Q4 Consensus; Apple Reaches 10m Goal
- Buy, Sell or Hold: BofA Will Strengthen as the Weak Perish
- How Much Will a Wells-Wachovia Deal Cost Taxpayers?
- Fannie and Freddie Did Not Cause This Crisis
- 36 Opportunities for the Beginning of the Bull
- Full list of Editor's Picks »
- Iceland: When Too Big to Fail Becomes Too Big to Rescue »
- Who Is Now Number One in the Banking Industry? »
- 25 Cash Cows to Ride Out the Storm- Barron's »
- 36 Opportunities for the Beginning of the Bull »
- Bailout Bill Passes; What Happens Now? »
- 3 Stocks That Are Begging To Be Bought »
- Citi Examines Its Carrots and Sticks »
- Five Energy Companies That Spell Opportunity »
- Thrown Overboard - Fast Money Recap (10/3/08) »
- Now's the Time to Buy Bank Stocks »
- Big Tech Prepares for Big Layoffs »
-
Long Ideas
-
Short Ideas
-
Cramer's Picks
- Opportunity in Emerging Markets Amidst This Panic
- A Stock the Average Joe Can Understand: The St. Joe Co.
- Accumulating Value Stocks: Good Any Time
- Are Puts the Best Way to Play UST and Anheuser-Busch?
- 10 Foreign Pink Sheet Traded 'Blue Chips'
- Buy, Sell or Hold: BofA Will Strengthen as the Weak Perish
- GE Looks Very Attractive Here
- Concentrated Solar Power & the New ITC: Big Winners of the Bailout Package
- Two Exciting Brazilian Oil Stocks
- Take a Look at Junk - Barron's
- Full list of Long Ideas »
- Gaming Stocks Still a Poor Bet - Barron's
- After Coming Rate Cuts, Some Appealing Short ETFs
- M/I Homes: Common Share Price Perplexing
- Trading ERO This Week
- Talk Me Down From the Wells Fargo Ledge
- SKF Regaining Its Old Form?
- Continuing Haircut in DST's Investment Portfolio
- Fortis and Bradford and Bingley Banks Thrown Lifelines
- The Short Case on KBH Homes
- International Game Technology: Good Short Opportunity
- Full list of Short Ideas »
- Musical Chairs - Cramer's Mad Money (10/3/08)
- Not Much to Recommend - Cramer's Lightning Round (10/3/08)
- Imminent Rate Cut? - Cramer's Stop Trading! (10/3/08)
- American Express to the Sell Block - Cramer's Mad Money (10/2/08)
- Buy Rarely; Sell Repeatedly - Cramer's Lightning Round (10/2/08)
- Any Kind of Return - Cramer's Stop Trading! (10/2/08)
- Throw Everything At It - Cramer's Mad Money (10/1/08)
- No Buy Recommendations - Cramer's Lightning Round (10/1/08)
- Another Buffet Buy - Cramer's Stop Trading! (10/1/08)
- Speculation Can Be Fun - Cramer's Mad Money Recap (9/30/08)
- Full list of Cramers Picks »
Trading Center
Hedge Fund Jobs
Job Seekers: Search jobs by category, get job alerts by email or live feed, apply online See full list of jobs »
Employers: See all recruitment options, get applications online or by email Post a job »



This article has 6 comments:
The brain, as I'm sure you know, is an "immuno-privilege... site-- that is, normally immune cells never enter the brain unless explicitly instructed to do so (e.g. with a vaccine). Leukocytes are not "trained" not to react to brain antigens they way they are with almost every other antigen in the body so the brain doesn't become the accidental target of damaging inflammation. Any sort of vaccine could induce that vaccination-- ACN-1792 was stopped in its tracks in pIIa because of that very inflammation problem.
Elan is all excited because, even though their active vaccination didn't show much in the way of cognitive improvement, iautopsies of dead patients pII trials showed plaque regression. However, replacing one neurological disease with another isn't ideal and would probably only be OK'd for extreme cases. I am unimpressed.
The passive vaccination (AB-001) is safer, and indeed it seems to work better (even though in my opinion it's still risky). Nonetheless, passive immunization is not nearly as sexy as an active immunization that could work prophylactically to cure Alzheimers like we cured Polio. The word "vaccine" has people all excited when perhaps they shouldn't be.
Even passive immunization to beta-amyloid, though, vaguely misses the mark. It doesn't nip the problem in the bud. A secretase inhibitor-- something in Elan's pipeline-- would be able to nip the problem in the bud. However, it's years and years away...
I'm intrigued and think that perhaps I will write up a full review of immunotherapies for Alzheimer disease... bestofbiotech.wordpres...
Replace "vaccination"... with "inflammation.&qu... My bad.